Surgical results after downstaging of initially marginal or non-resectable liver metastases

Digestive Diseases

Volumn 30, Issue SUPPL.2, 2012, Pages 143-149

  Cauchy, F ^a   Faivre, S ^a   Belghiti, J ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

Chemotherapy; Colorectal liver metastases; Downstaging; Initial unresectability; Liver resection

Indexed keywords

BEVACIZUMAB; CETUXIMAB; IRINOTECAN; OXALIPLATIN;

ANTIANGIOGENIC THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; COLORECTAL LIVER METASTASIS; CONFERENCE PAPER; DRUG SAFETY; HUMAN; INOPERABLE CANCER; LIVER METASTASIS; LIVER RESECTION; LIVER VENOOCCLUSIVE DISEASE; LONG TERM SURVIVAL; METASTASIS RESECTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; NEOPLASM STAGING; TREATMENT OUTCOME;

EID: 84870819269     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000342048     Document Type: Conference Paper

References (88)

1. Fong Y, Fortner J, Sun RL, et al: Clinicalscore for predicting recurrence after hepaticresection for metastatic colorectal cancer:analysis of 1,001 consecutive cases. Ann Surg1999; 230: 309-318.
2. Adam R, Delvart V, Pascal G, et al: Rescuesurgery for unresectable colorectal liver metastasesdownstaged by chemotherapy: amodel to predict long-term survival. AnnSurg 2004; 240: 644-657.
3. Wicherts DA, Miller R, de Haas RJ, et al:Long-term results of two-stage hepatectomyfor irresectable colorectal cancer liver metastases.Ann Surg 2008; 248: 994-1005.
4. Wicherts DA, de Haas RJ, Andreani P, et al:Impact of portal vein embolization on longtermsurvival of patients with primarily unresectablecolorectal liver metastases. Br JSurg 2010; 97: 240-250.
5. Brouquet A, Abdalla EK, Kopetz S, et al:High survival rate after two-stage resectionof advanced colorectal liver metastases: response-based selection and complete resectiondefine outcome. J Clin Oncol 2011; 29:1083-1090.
6. Narita M, Oussoultzoglou E, Jaeck D, et al:Two-stage hepatectomy for multiple bilobarcolorectal liver metastases. Br J Surg 2011; 98:1463-1475.
7. Folprecht G, Gruenberger T, Bechstein WO,et al: Tumour response and secondary resectabilityof colorectal liver metastases followingneoadjuvant chemotherapy with cetuximab:the CELIM randomised phase 2trial. Lancet Oncol 2010; 11: 38-47.
8. Goéré D, Gaujoux S, Deschamp F, et al: Patientsoperated on for initially unresectablecolorectal liver metastases with missing metastasesexperience a favorable long-termoutcome. Ann Surg 2011; 254: 114-118.
9. Pawlik TM, Schulick RD, Choti MA: Expandingcriteria for resectability of colorectalliver metastases. Oncologist 2008; 13: 51-64.
10. de Haas RJ, Wicherts DA, Andreani P, et al:Impact of expanding criteria for resectabilityof colorectal metastases on short-and longtermoutcomes after hepatic resection. AnnSurg 2011; 253: 1069-1079.
11. Adam R, de Haas RJ, Wicherts DA, et al:Concomitant extrahepatic disease in patientswith colorectal liver metastases: whenis there a place for surgery? Ann Surg 2011;253: 349-359.
12. Brouquet A, Vauthey JN, Contreras CM, etal: Improved survival after resection of liverand lung colorectal metastases comparedwith liver-only metastases: a study of 112 patientswith limited lung metastatic disease. JAm Coll Surg 2011; 213: 62-69.
13. Adam R, Pascal G, Castaing D, et al: Tumorprogression while on chemotherapy: a contraindicationto liver resection for multiplecolorectal metastases? Ann Surg 2004; 240:1052-1061.
14. Brouquet A, Overman MJ, Kopetz S, et al: Isresection of colorectal liver metastases aftera second-line chemotherapy regimen justified?Cancer 2011; 117: 4484-4492.
15. Cauchy F, Aussilhou B, Dokmak S, et al: Reappraisalof the risks and benefits of majorliver resection for patients with initially unresectablecolorectal liver metastases. AnnSurg 2012, in press.
16. Hurwitz H, Fehrenbacher L, Novotny W, etal: Bevacizumab plus irinotecan, fluorouracil,and leucovorin for metastatic colorectalcancer. N Engl J Med 2004; 350: 2335-2342.
17. Goéré D, Deshaies I, de Baere T, et al: Prolongedsurvival of initially unresectable hepaticcolorectal cancer patients treated withhepatic arterial infusion of oxaliplatin followedby radical surgery of metastases. AnnSurg 2010; 251: 686-691.
18. House MG, Kemeny NE, Gönen M, et al:Comparison of adjuvant systemic chemotherapywith or without hepatic arterial infusionalchemotherapy after hepatic resectionfor metastatic colorectal cancer. AnnSurg 2011; 254: 851-856.
19. Blazer DG 3rd, Kishi Y, Maru DM, et al:Pathologic response to preoperative chemotherapy: A new outcome end point after resectionof hepatic colorectal metastases. JClin Oncol 2008; 26: 5344-5351.
20. Poultsides GA, Bao F, Servais EL, et al:Pathologic response to preoperative chemotherapyin colorectal liver metastases: fibrosis,not necrosis, predicts outcome. Ann SurgOncol 2012, E-pub ahead of print.
21. Maru DM, Kopetz S, Boonsirikamchai P, et al:Tumor thickness at the tumor-normal interface: A novel pathologic indicator of chemotherapyresponse in hepatic colorectal metastases.Am J Surg Pathol 2010; 34: 1287-1294.
22. Van Kessel CS, Buckens CF, van den BoschMA, et al: Preoperative imaging of colorectalliver metastases after neoadjuvant chemotherapy: A meta-analysis. Ann Surg Oncol2012, E-pub ahead of print.
23. Chun YS, Vauthey JN, Boonsirikamchai P,et al: Association of computed tomographymorphologic criteria with pathologic responseand survival in patients treated withbevacizumab for colorectal liver metastases.JAMA 2009; 302: 2338-2344.
24. Therasse P, Arbuck SG, Eisenhauer EA, et al:New guidelines to evaluate the response totreatment in solid tumors. European Organizationfor Research and Treatment of Cancer,National Cancer Institute of the UnitedStates, National Cancer Institute of Canada.J Natl Cancer Inst 2000; 92: 205-216.
25. Eisenhauer EA, Therasse P, Bogaerts J, et al:New response evaluation criteria in solid tumours:revised RECIST guideline (version1.1). Eur J Cancer 2009; 45: 228-247.
26. Aloia T, Sebagh M, Plasse M, et al: Liver histologyand surgical outcomes after preoperativechemotherapy with fluorouracil plus oxaliplatinin colorectal cancer liver metastases.J Clin Oncol 2006; 24: 4983-4990.
27. Karoui M, Penna C, Amin-Hashem M, et al:Influence of preoperative chemotherapy onthe risk of major hepatectomy for colorectalliver metastases. Ann Surg 2006; 243: 1-7.
28. Narita M, Oussoultzoglou E, Chenard MP, etal: Liver injury due to chemotherapy-inducedsinusoidal obstruction syndrome isassociated with sinusoidal capillarization.Ann Surg Oncol 2012; 19: 2230-2237.
29. Rubbia-Brandt L, Audard V, Sartoretti P, etal: Severe hepatic sinusoidal obstruction associatedwith oxaliplatin-based chemotherapyin patients with metastatic colorectal cancer.Ann Oncol 2004; 15: 460-466.
30. Soubrane O, Brouquet A, Zalinski S, et al:Predicting high grade lesions of sinusoidalobstruction syndrome related to oxaliplatinbasedchemotherapy for colorectal liver metastases:correlation with post-hepatectomyoutcome. Ann Surg 2010; 251: 454-460.
31. Wicherts DA, de Haas RJ, Sebagh M, et al:Regenerative nodular hyperplasia of the liverrelated to chemotherapy: impact on outcomeof liver surgery for colorectal metastases.Ann Surg Oncol 2011; 18: 659-669.
32. Hubert C, Sempoux C, Horsmans Y, et al:Nodular regenerative hyperplasia: a deleteriousconsequence of chemotherapy forcolorectal liver metastases? Liver Int 2007; 27:938-943.
33. Wicherts DA, de Haas RJ, Sebagh M, et al:Impact of bevacizumab on functional recoveryand histology of the liver after resectionof colorectal metastases. Br J Surg 2011; 98:399-407.
34. Ribero D, Wang H, Donadon M, et al: Bevacizumabimproves pathologic response andprotects against hepatic injury in patientstreated with oxaliplatin-based chemotherapyfor colorectal liver metastases. Cancer2007; 110: 2761-2767.
35. Klinger M, Eipeldauer S, Hacker S, et al: Bevacizumabprotects against sinusoidal obstructionsyndrome and does not increaseresponse rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer livermetastases. Eur J Surg Oncol 2009; 35: 515-520.
36. Fernandez FG, Ritter J, Goodwin JW, et al:Effect of steatohepatitis associated with irinotecanor oxaliplatin pretreatment on resectabilityof hepatic colorectal metastases. JAm Coll Surg 2005; 200: 845-853.
37. Vauthey JN, Pawlik TM, Ribero D, et al: Chemotherapyregimen predicts steatohepatitisand an increase in 90-day mortality aftersurgery for hepatic colorectal metastases. JClin Oncol 2006; 24: 2065-2072.
38. Raptis DA, Fischer MA, Graf R, et al: MRI:the new reference standard in quantifyinghepatic steatosis? Gut 2012; 61: 117-127.
39. Ratziu V, Charlotte F, Heurtier A, et al: Samplingvariability of liver biopsy in nonalcoholicfatty liver disease. Gastroenterology2005; 128: 1898-1906.
40. Merriman RB, Ferrell LD, Patti MG, et al:Correlation of paired liver biopsies in morbidlyobese patients with suspected nonalcoholicfatty liver disease. Hepatology 2006; 44:874-880.
41. Kleiner DE, Brunt EM, Van Natta M, et al:Design and validation of a histological scoringsystem for nonalcoholic fatty liver disease.Hepatology 2005; 41: 1313-1321.
42. Belghiti J, Noun R, Malafosse R, et al: Continuousversus intermittent portal triadclamping for liver resection: a controlledstudy. Ann Surg 1999; 229: 369-375.
43. Veteläinen R, van Vliet A, Gouma DJ, et al:Steatosis as a risk factor in liver surgery. AnnSurg 2007; 245: 20-30.
44. McCormack L, Petrowsky H, Jochum W, etal: Hepatic steatosis is a risk factor for postoperativecomplications after major hepatectomy: A matched case-control study. AnnSurg 2007; 245: 923-930.
45. de Meijer VE, Kalish BT, Puder M, et al: Systematicreview and meta-analysis of steatosisas a risk factor in major hepatic resection. BrJ Surg 2010; 97: 1331-1339.
46. Gomez D, Malik HZ, Bonney GK, Wong, etal: Steatosis predicts postoperative morbidityfollowing hepatic resection for colorectalmetastasis. Br J Surg 2007; 94: 1395-1402.
47. Brouquet A, Benoist S, Julie C, et al: Risk factorsfor chemotherapy-associated liver injuries: A multivariate analysis of a group of 146patients with colorectal metastases. Surgery2009; 145: 362-371.
48. Aussilhou B, Dokmak S, Faivre S: Preoperativeliver hypertrophy induced by portal flowocclusion before major hepatic resection forcolorectal metastases can be impaired by bevacizumab.Ann Surg Oncol 2009; 16: 1553-1559.
49. Zorzi D, Chun YS, Madoff DC, et al: Chemotherapywith bevacizumab does not affectliver regeneration after portal vein embolizationin the treatment of colorectal livermetastases. Ann Surg Oncol 2008; 15: 2765-2772.
50. Azoulay D, Castaing D, Smail A, et al: Resectionof nonresectable liver metastases fromcolorectal cancer after percutaneous portalvein embolization. Ann Surg 2000; 231: 480-486.
51. Elias D, Ouellet JF, De Baère T, et al: Preoperativeselective portal vein embolization beforehepatectomy for liver metastases: longtermresults and impact on survival. Surgery2002; 131: 294-299.
52. Farges O, Belghiti J, Kianmanesh R, et al:Portal vein embolization before right hepatectomy:prospective clinical trial. Ann Surg2003; 237: 208-217.
53. Hemming AW, Reed AI, Howard RJ, et al:Preoperative portal vein embolization forextended hepatectomy. Ann Surg 2003; 237:686-691.
54. Jaeck D, Oussoultzoglou E, Rosso E, et al: Atwo-stage hepatectomy procedure combinedwith portal vein embolization to achieve curativeresection for initially unresectablemultiple and bilobar colorectal liver metastases.Ann Surg 2004; 240: 1037-1049.
55. Pamecha V, Glantzounis G, Davies N, et al:Long-term survival and disease recurrencefollowing portal vein embolisation prior tomajor hepatectomy for colorectal metastases.Ann Surg Oncol 2009; 16: 1202-1207.
56. Abdalla EK, Adam R, Bilchik AJ, et al: Improvingresectability of hepatic colorectalmetastases: expert consensus statement.Ann Surg Oncol 2006; 13: 1271-1280.
57. Narita M, Oussoultzoglou E, Fuchshuber P,et al: What is a safe future liver remnant sizein patients undergoing major hepatectomyfor colorectal liver metastases and treated byintensive preoperative chemotherapy? AnnSurg Oncol 2012; 19: 2526-2538.
58. Aussilhou B, Lesurtel M, Sauvanet A, et al:Right portal vein ligation is as efficient asportal vein embolization to induce hypertrophyof the left liver remnant. J GastrointestSurg 2008; 12: 297-303.
59. Capussotti L, Muratore A, Baracchi F, et al:Portal vein ligation as an efficient method ofincreasing the future liver remnant volumein the surgical treatment of colorectal metastases.Arch Surg 2008; 143: 978-982.
60. de Baere T, Teriitehau C, Deschamps F, et al:Predictive factors for hypertrophy of the futureremnant liver after selective portal veinembolization. Ann Surg Oncol 2010; 17:2081-2089.
61. Elias D, De Baere T, Roche A, et al: Duringliver regeneration following right portal embolizationthe growth rate of liver metastasesis more rapid than that of the liver parenchyma.Br J Surg 1999; 86: 784-788.
62. Kokudo N, Tada K, Seki M, et al: Proliferativeactivity of intrahepatic colorectal metastasesafter preoperative hemihepatic portalvein embolization. Hepatology 2001; 34: 267-272.
63. Schnitzbauer AA, Lang SA, Goessmann H, etal: Right portal vein ligation combined within situ splitting induces rapid left lateral liverlobe hypertrophy enabling 2-staged extendedright hepatic resection in small-for-size settings.Ann Surg 2012; 255: 405-414.
64. Mise Y, Hasegawa K, Satou S, et al: Venousreconstruction based on virtual liver resectionto avoid congestion in the liver remnant.Br J Surg 2011; 98: 1742-1751.
65. Azoulay D, Eshkenazy R, Andreani P, et al:In situ hypothermic perfusion of the liverversus standard total vascular exclusion forcomplex liver resection. Ann Surg 2005; 241:277-285.
66. Varma D, Ogata S, Belghiti J: Isolated totalcaval clamping with 'preserved remnant liverperfusion' for combined hepatic and venacavalresection in tumors involving venacava.Surgery 2007; 141: 112-116.
67. Bachellier P, Rosso E, Pessaux P, et al: Riskfactors for liver failure and mortality afterhepatectomy associated with portal vein resection.Ann Surg 2011; 253: 173-179.
68. DeMatteo RP, Palese C, Jarnagin WR, et al:Anatomic segmental hepatic resection is superiorto wedge resection as an oncologic operationfor colorectal liver metastases. J GastrointestSurg 2000; 4: 178-184.
69. Zorzi D, Mullen JT, Abdalla EK, et al: Comparisonbetween hepatic wedge resection andanatomic resection for colorectal liver metastases.J Gastrointest Surg 2006; 10: 86-94.
70. Sarpel U, Bonavia AS, Grucela A, et al: Doesanatomic versus nonanatomic resection affectrecurrence and survival in patients undergoingsurgery for colorectal liver metastasis?Ann Surg Oncol 2009; 16: 379-384.
71. Finch RJ, Malik HZ, Hamady ZZ, et al: Effectof type of resection on outcome of hepaticresection for colorectal metastases. Br J Surg2007; 94: 1242-1248.
72. Bodingbauer M, Tamandl D, Schmid K, et al:Size of surgical margin does not influencerecurrence rates after curative liver resectionfor colorectal cancer liver metastases. Br JSurg 2007; 94: 1133-1138.
73. Pawlik TM, Scoggins CR, Zorzi D, et al: Effectof surgical margin status on survival andsite of recurrence after hepatic resection forcolorectal metastases. Ann Surg 2005; 241:715-722.
74. Hamady ZZ, Cameron IC, Wyatt J, et al: Resectionmargin in patients undergoing hepatectomyfor colorectal liver metastasis: a criticalappraisal of the 1 cm rule. Eur J Surg Oncol2006; 32: 557-563.
75. Figueras J, Burdio F, Ramos E, et al: Effect ofsubcentimeter nonpositive resection marginon hepatic recurrence in patients undergoinghepatectomy for colorectal liver metastases.Evidences from 663 liver resections. AnnOncol 2007; 18: 1190-1195.
76. Mentha G, Terraz S, Morel P, et al: Dangeroushalo after neoadjuvant chemotherapyand two-step hepatectomy for colorectal livermetastases. Br J Surg 2009; 96: 95-103.
77. De Haas RJ, Wicherts DA, Flores E, et al: R1resection by necessity for colorectal liver metastases:is it still a contraindication to surgery?Ann Surg 2008; 248: 626-637.
78. Are C, Gonen M, Zazzali K, et al: The impactof margins on outcome after hepatic resectionfor colorectal metastasis. Ann Surg2007; 246: 295-300.
79. Shirabe K, Takenaka K, Gion T, et al: Analysisof prognostic risk factors in hepatic resectionfor metastatic colorectal carcinomawith special reference to the surgical margin.Br J Surg 1997; 84: 1077-1080.
80. Wakai T, Shirai Y, Sakata J, et al: Appraisal of1 cm hepatectomy margins for intrahepaticmicrometastases in patients with colorectalcarcinoma liver metastasis. Ann Surg Oncol2008; 15: 2472-2481.
81. Benoist S, Brouquet A, Penna C, et al: Completeresponse of colorectal liver metastasesafter chemotherapy: does it mean cure? JClin Oncol 2006; 24: 3939-3945.
82. Ito H, Are C, Gonen M, et al: Effect of postoperativemorbidity on long-term survivalafter hepatic resection for metastatic colorectalcancer. Ann Surg 2008; 247: 994-1002.
83. Laurent C, Sa Cunha A, Couderc P, et al: Influenceof postoperative morbidity on longtermsurvival following liver resection forcolorectal metastases. Br J Surg 2003; 90:1131-1136.
84. Elias D, Manganas D, Benizri E, et al: Thetrans-metastasis hepatectomy (through metastasespreviously ablated with radiofrequency):results of a 13-case study of colorectalcancer. J Surg Oncol 2006; 93: 8-12.
85. Adam R, Bismuth H, Castaing D, et al: Repeathepatectomy for colorectal liver metastases.Ann Surg 1997; 225: 51-60.
86. Muratore A, Polastri R, Bouzari H, et al: Repeathepatectomy for colorectal liver metastases: A worthwhile operation? J Surg Oncol2001; 76: 127-132.
87. Adam R, Pascal G, Azoulay D, et al: Liver resectionfor colorectal metastases: the thirdhepatectomy. Ann Surg 2003; 238: 871-883.
88. Andreou A, Brouquet A, Abdalla EK, et al:Repeat hepatectomy for recurrent colorectalliver metastases is associated with a high survivalrate. HPB (Oxford) 2011; 13: 774-782.